Sigilon Therapeutics Inc. (NASDAQ: SGTX) shares settled at $14.95 in after-market trades, rising 7.55%. A price of $13.90 was reached Friday by Sigilon stock, closing the session -5.70% lower. There were 0.25 million shares of SGTX stock traded in the last session, which was more than 50-day average volume of 0.13 million shares. Within the past 30 days, SGTX stock gained only -37.81% while falling by -8.97% for the past week. Upon selection of its abstract to be presented at a research society event, SGTX stock rose.
What were the abstracts?
A core goal of Sigilon Therapeutics’ Shielded Living Therapeutics (SLTx) platform is to discover and develop functional treatments for chronic diseases. SGTX product candidates are cell-based therapies that do not contain viruses but instead are designed to help patients suffering from hemophilia, lysosomal disorders (LLD), diabetes or other chronic diseases. Afibromer, SGTX’s biomaterials matrix, protects those engineered cells from rejection by the immune system and from fibrosis.
In the last week, Sigilon Therapeutics announced that four abstracts would be presented on the 24thannual convention of the American Society of Gene and Cell Therapy (ASGCT) to be held virtually from May 11-14, 2021.
These presentations include preliminary results from SGTX’s study on immune-mediated hepatitis and hypoparathyroidism using its cutting-edge SLTx technology, which reflects the modularity and development potential of Sigilon’s pipeline.
ASGCT will make the SGTX’s presentations available on its website starting on May 11th, 2021 at 8:00 AM EDT. After the presentations, the following four posters will be added to the Publications section of SGTX’s corporate website.
- “A Scaled and Semi-Automated Cell Encapsulation Process for a Shielded Cell-Based Platform for Chronic Diseases”
- “Continuous Delivery of IL-10 Using the Shielded Living TherapeuticsTM Platform Leads to Modulation of Immune Cell Function and Prevents Liver Damage in Preclinical Model of Immune-Mediated Hepatitis”
- “Tunable Delivery of Parathyroid Hormone with the Shielded Living TherapeuticsTM Platform Provides a New Modality for Treatment of Hypoparathyroidism”
- “Analytical Development Considerations for the Shielded Living TherapeuticsTM Platform: A Novel Encapsulated Cell-Based, Non-Viral Platform for Delivery of Therapeutic Proteins”
What SGTX has achieved?
With current therapies for immune-mediated and metabolic disorders carrying many limitations, Sigilon Therapeutics (SGTX) demonstrated the potential to overcome them.